BACKGROUND: The frequency of epithelial cell adhesion molecule (EpCAM) expression was investigated in non-small cell lung cancer (NSCLC) cells and human tissues, and its clinicopathological significance in adenocarcinoma of the lung was evaluated. MATERIALS AND METHODS: EpCAM expression was analysed by reverse transcription-polymerase chain reaction (RT-PCR) and flow cytometry in human NSCLC cells. EpCAM protein expression was evaluated in 234 adenocarcinoma tissues using immunohistochemistry. RESULTS: A high expression level of EpCAM was observed in human NSCLC cells by flow cytometry and RT-PCR. EpCAM overexpression was detected in 120/234 (51.3%) surgically resected adenocarcinoma tissues. EpCAM overexpression occurred significantly more frequently in adenocarcinoma than in bronchioloalveolar carcinoma (p=0.02). The overall survival did not differ significantly between EpCAM-overexpressing and EpCAM-negative patients (p=0.40). CONCLUSION: These findings suggest EpCAM plays a role in the carcinogenesis of adenocarcinoma of the lung and might provide a promising molecule for targeted therapy in NSCLC.
BACKGROUND: The frequency of epithelial cell adhesion molecule (EpCAM) expression was investigated in non-small cell lung cancer (NSCLC) cells and human tissues, and its clinicopathological significance in adenocarcinoma of the lung was evaluated. MATERIALS AND METHODS:EpCAM expression was analysed by reverse transcription-polymerase chain reaction (RT-PCR) and flow cytometry in humanNSCLC cells. EpCAM protein expression was evaluated in 234 adenocarcinoma tissues using immunohistochemistry. RESULTS: A high expression level of EpCAM was observed in humanNSCLC cells by flow cytometry and RT-PCR. EpCAM overexpression was detected in 120/234 (51.3%) surgically resected adenocarcinoma tissues. EpCAM overexpression occurred significantly more frequently in adenocarcinoma than in bronchioloalveolar carcinoma (p=0.02). The overall survival did not differ significantly between EpCAM-overexpressing and EpCAM-negative patients (p=0.40). CONCLUSION: These findings suggest EpCAM plays a role in the carcinogenesis of adenocarcinoma of the lung and might provide a promising molecule for targeted therapy in NSCLC.
Authors: Robert M Gemmill; Joëlle Roche; Vincent A Potiron; Patrick Nasarre; Michael Mitas; Chris D Coldren; Barbara A Helfrich; Elizabeth Garrett-Mayer; Paul A Bunn; Harry A Drabkin Journal: Cancer Lett Date: 2010-10-25 Impact factor: 8.679
Authors: Erik A Rodriguez; Ye Wang; Jessica L Crisp; David R Vera; Roger Y Tsien; Richard Ting Journal: Bioconjug Chem Date: 2016-04-27 Impact factor: 4.774
Authors: S Karabulut; F Tas; D Tastekin; M Karabulut; C T Yasasever; R Ciftci; M Güveli; M Fayda; S Vatansever; M Serilmez; R Disci; A Aydıner Journal: Tumour Biol Date: 2014-06-03
Authors: Jay F Dorsey; Gary D Kao; Kelly M MacArthur; Melody Ju; David Steinmetz; E Paul Wileyto; Charles B Simone; Stephen M Hahn Journal: Cancer Date: 2014-09-19 Impact factor: 6.860
Authors: Melissa A Frick; Gary D Kao; Louise Aguarin; Chimbu Chinniah; Samuel Swisher-McClure; Abigail T Berman; William P Levin; Keith A Cengel; Cristina DeCesaris; Stephen M Hahn; Jay F Dorsey; Charles B Simone Journal: Int J Radiat Oncol Biol Phys Date: 2018-07-02 Impact factor: 7.038